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RIASSUNTO 
 
Efficienza del processo di exon-skipping indotto da 
oligonucleotidi antisenso nel gene DMD, wild type e mutato 
 
 
La distrofia mscolare di Duchenne: 
 
La distrofia muscolare di Duchenne (DMD) è la più frequente malattia recessiva 
legata al sesso, con un’incidenza di circa 1 su 3500 maschi nati vivi. 
I pazienti affetti da DMD sono solitamente costretti su sedia a rotelle dall’età di 
12 anni e soccombono per insufficienza respiratoria o cardiaca verso la seconda 
decade d’età. 
La  distrofia  muscolare  di  Becker  (BMD)  è  la  forma  allelica  della  DMD  con 
manifestazione  più  lieve;  i  pazienti  possono  arrivare  a  manifestare  difficoltà 
motorie anche dopo i 40 anni, la qualità e l’aspettativa di vita sono decisamente 
migliori che non nella DMD (Wells et al., 2002). 
 
Gene, proteine e struttura: 
 
Mutazioni nel gene della distofina (DMD) portano alle due malattie. La proteina 
sintetizzata da questo gene ha un importante ruolo strutturale nell’ancorare il 
citoscheletro  al  sarcolemma  favorendo  l’integrità  strutturale  del  muscolo 
durante la contrazione, è inoltre in parte responsabile della trasmissione della 
forza motrice prodotta al resto della massa muscolare e quindi nel risultante 
movimento. 
Il gene DMD è situato sul cromosoma X, nella regione p21. È il gene più lungo 
dell’intero genoma umano, copre 2,4 megabasi e comprende 79 esoni intervallati 
da larghe sequenze introniche. Esistono almeno 7 forme alternative di prodotto 
trascitto, che comprendono 3 forme full-length (con risultanti proteine di 427 
kDa) e almeno altri 4 promotori che codificano per le cosiddette “forme corte”. I 
promotori delle forme full-length prendono il nome dal principale (ma non unico) 
sito di espressione; si hanno i promotori muscolare (M), cerebrale (C) e Purkinje 
(P). Le forme corte sono variamente espresse nei tessuti e coesistono spesso con 
le forme lunghe (Muntoni et al., 2003). 
La proteina è strutturata in 4 domini distinti: 
- Il domio N-terminale che lega l’actina nel citoplasma RIASSUNTO 
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- Il dominio spectrino-simile che consiste di 24 sequenze ripetute le quali 
conferiscono proprietà elastiche alla proteina 
- Il dominio ricco in cisteine fondamentale per l’ancoraggio della proteina 
al sarcolemma 
- Il dominio C-terminale o coiled-coil (CC) dove si hanno la gran parte delle 
interazioni con altre proteine. 
La distrofina si lega ad un complesso reticolo di proteine situato sul sarcolemma; 
queste  proteine  di  varia  natura  e  funzione  sono  per  la  maggior  parte  trans-
membrana e formano il cosiddetto “complesso associato alla distrofina” (DGC o 
DAPC). Le proteine del DGC legano sul versante citoplasmatico la parte terminale 
della distrofina, mentre sul lato esterno della cellula si legano a varie proteine 
della laminina basale (Roberts, 2001). 
 
Filogenesi: 
 
La distrofina è riconosciuta come la capostipite di una superfamiglia di proteine 
che è presente in tutto il regno animale; le regioni distintive di questa famiglia 
sono la regione ricca in cisteine e quella CC. 
La filogenesi di questa superfamiglia origina da un antenato non metazoo da cui 
si sono separate due nuove famiglie proteiche: le distrofine e le distrobrevine. 
Queste  due  famiglie  hanno  poi  seguito  strade  diverse  fra  i  vertebrati  e  gli 
invertebrati. 
Nei  vertebrati  il  ramo  delle  distrofine  ha  dato  luogo  prima  di  tutto  alla 
sottofamiglia  DRP2  (dystrophin  related  protein  2)  e  successivamente  alla 
divisione fra utrofina e distrofina. Sul ramo delle distrobrevine invece si sono 
originati due geni paraloghi codificanti per l’ -distrobrevina e la  -distrobrevina. 
Negli  invertebrati  il  repertorio  delle  proteine  è  rimasto  più  semplice, 
mantenendo solo una famiglia per ramo, le proteine distrofino- e distrobrevino-
simili.  Tali  proteine  sono  tuttavia  molto  conservate,  ad  indice  della  loro 
importanza funzionale e strutturale (Jin et al., 2007). 
 
Animali modello: 
 
Mutazioni  nel  gene  DMD  sono  state  riportate  in  molti  animali  vertebrati  ed 
anche nei geni ortologhi degli invertebrati. 
Il  modello  murino  per  lo  studio  della  malattia  è  il  topo  mdx.  Questo  ceppo 
presenta una mutazione non senso nell’esone 23 che porta ad un messaggero 
troncato.  Il  facile  allevamento  gestione  per  le  dimensioni  e  la  gestione 
dell’animale lo hanno reso il modello più utilizzato nella ricerca per la DMD. Il RIASSUNTO 
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fenotipo  risultante  dalla  mutazione  tuttavia  presenta  molte  differenze  con  la 
patologia umana. 
Oltre al topo esiste anche un modello canino che riproduce più fedelmente la 
patologia umana e viene usato in studi più avanzati date le difficoltà di gestione 
di tali animali (Willmann et al., 2009). 
Gli  invertebrati  hanno  fornito  negli  anni  importanti  informazioni  a  livello 
molecolare e funzionale sulla distrofina e le proteine ad essa correlate (Wells et 
al., 2005). 
 
Patogenesi: 
 
La patogenesi della malattia vede l’insorgere di fibre necrotiche (solitamente in 
gruppo)  e  alcune  piccole  fibre  centro  nucleate  (indice  di  rigenerazione 
muscolare). Con il passare del tempo il bilancio fra le capacità rigenerative del 
muscolo  di  far  fronte  alle  fibre  che  vanno  in  necrosi  viene  meno  e  le  fibre 
muscolari  sono  progressivamente  sostituite  da  tessuto  adiposo  e  fibroso 
(Bockhold et al., 1998). 
Una  delle  principali  cause  di  morte  delle  cellule  si  pensa  sia  associata  alla 
conseguente fragilità della membrana delle cellule muscolari. L’influsso di calcio 
dall’ambiente extracellulare porterebbe ad un  aumento della concentrazione 
citoplasmatica  di  questo  ione,  che  con  il  tempo  non  potrebbe  essere  più 
controllata  da  meccanismi  fisiologici  e finirebbe  con  portare  alla  morte  delle 
cellule (Deconinck et al., 2007). 
 
Mutazioni: 
 
Dal punto di vista genetico il gene DMD presenta un alto tasso di mutazioni (van 
Essen et al., 1992), le quali possono essere collegate alla malattia ricorrendo alla 
“teoria del registro di lettura” secondo la quale in presenza di una mutazione che 
fa  slittare  il  normale  registro  di  lettura  del  trascritto  si  viene  a  creare  una 
proteina tronca e non funzionante che porta quindi al quadro patologico della 
malattia. Se la mutazione invece rispetta il registro di lettura allora si verrà a 
creare una proteina più corta ma in parte funzionante, come confermato da casi 
di pazienti con grandi regioni delete del gene con un fenotipo BMD o quasi non 
patologico, Questo è in parte dovuto al fatto che la proteina è costituita per più 
del 70% dalle sequenze ripetute del dominio spectrino-simile. È stato osservato 
che basta una minima porzione di tale regione della proteina per mantenere la 
sua funzionalità (Monaco et al., 1988). 
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Attuali terapie e ricerca: 
 
Gli  attuali  approcci  terapeutici  per  la  DMD  prevedono  l’uso  di  farmaci  come 
corticosteroidi per diminuire la manifestazione dei sintomi e migliorare il tono 
muscolare, ma questa categoria farmacologia non manca di controindicazioni. 
Alcuni tipi di antibiotici sono in grado di far saltare il registro di lettura dove vi sia 
una mutazione non senso (come nel topo mdx) consentendo così di sintetizzare 
una proteina mutata ma parzialmente funzionale, ma nell’essere umano questa 
strada è ancora in fase di accertamento e la paura di effetti di  read-through 
indesiderati fanno procedere con cautela (Yiu et al., 2008). 
In  assenza  di  distrofina  si  nota  una  aumentata  espressione  di  utrofina,  che 
potrebbe  supplire  alla  mancanza  della  prima,  ma  non  sono  normalmente 
raggiunti  i  livelli  richiesti  per  sopperire  al  fenotipo  distrofico,  alcune  linee  di 
ricerca si stanno incentrando su aumentare l’espressione di tale gene (Cossu et 
al., 2007). 
Il  trapianto  di  cellule  miogeniche  è  stato  ampiamente  affrontato  negli  ultimi 
anni; le caratteristiche che tali cellule devono presentare sono: la capacità di 
ripristinare muscolo funzionante, non indurre risposta immunitaria, consentire la 
loro  riproduzione  per  mantenere  intatto  un  pool  rigenerativo  ed  essere 
terapeuticamente valide come trattamento (Price et al., 2007). 
Sono  stati  inoltre  studiati  diversi  modi  per  indurre  la  produzione  di  forme 
funzionanti  di  distrofina  per  esempio  tramite  l’inserimento  di  geni  esogeni 
tramite vettori virali, che andrebbero a fornire alle cellule distrofiche una copia 
da usare in sostituzione alla propria (Yiu et al., 2008). 
 
Terapia tramite oligonucleotidi antisenso: 
Negli  ultimi  anni  un  nuovo  approccio  si  sta  facendo  strada,  ovvero  quello  di 
indurre  l’esclusione  di  ulteriori  esoni  dal  pre-mRNA.  A  prima  vista  questo 
sembrerebbe  insensato,  ma  se  si  pensa  al  fatto  che  così  facendo  si  può 
ripristinare  il  registro  di  lettura  originario,  allora  si  può  capire  la  validità 
terapeutica di questo approccio. 
Gli  oligonucleotidi antisenso (AOs) possono produrre  effeti di “exon-skipping” 
durante il processamento del pre-mRNA. L’AO specifico si va a legare ad un sito 
appositamete studiato per interferire con il meccanismo di splicing della cellula, 
impedendo così l’inclusione di un esone nel trascritto finale, ottenendo così una 
proteina più corta ma parzialmente funzionale (Aartsma-Rus et al., 2007). 
Questa sarebbe una terapia ad hoc da effettuare per ogni singola mutazione che 
si vorrebbe curare, ma i vantaggi terapeutici sono molti: 
- Eliminerebbe il rischio delle terapie associate a trattamenti genici virali RIASSUNTO 
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- Permetterebbe il ripristino di tutte le forme di distrofina, non solo quella 
muscolare 
- Manterrebbe la normale regolazione tessuto-specifica nella produzione di 
distrofina 
- Seppure questa sia una terapia personalizzata la produzione dell’agente 
terapeutico non sarebbe dispendiosa e sarebbe molto semplice. 
Non ultimo il fatto che già normalmente questo fenomeno si presenta in gruppi 
isolati di cellule nel muscolo distrofico, validandone le basi teoriche (Lu et al., 
2000). 
Verosimilmente i pazienti potrebbero essere portati verso un fenotipo più simile 
alla BMD se non mostrare segni di assenza della distrofia. 
Per permettere la persistenza del trattamento gli AO sono stati modificati negli 
anni a livello della struttura molecolare dello scheletro o di modificazioni in 2’, 
così da rendere più resistenti le molecole alla degradazione cellulare da parte 
delle endonucleasi presenti nelle cellule. 
 
 
 
Scopo della tesi: 
 
In questo lavoro di tesi si è andati ad indagare l’efficacia di alcuni oligonucleotidi 
antisenso progettati per escludere alcuni esoni da sequenze “sane”. Le cellule dei 
pazienti utilizzate in questo lavoro invece presentano molte variazioni a livello di 
delezioni/mutazioni nel trascritto e si è voluto verificare l’applicabilità degli AO 
ad un contesto “mutato”. 
Le cellule dei pazienti sono state derivate da biopsie depositate nella banca di 
campioni bioptici di Telethon a Milano (in collaborazione con l’istituto Besta di 
Milano),  mentre  quelle  dei  donatori  sani  dalla  banca  Telethon  di  Padova  (in 
collaborazione con la Dott.ssa M. Fanin). 
Sono  stati  impiegati  oligonucleotidi  2’-O-metil-fosforotioati  modificati, 
sintetizzati in collaborazione con il laboratorio del Dott. S. J. Wilton. 
Per  fare  questo  si  sono  trasfettati  dei  mioblasti  di  pazienti  in  coltura  per 
introdurre le molecole nelle cellule e consentire lo skipping. 
Sono inoltre state effettuate prove di verifica della presenza di distrofina tramite 
immunofluorescenza. 
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Risultati: 
 
Nelle prove effettuate si è andata a verificare l’efficienza dello skipping da parte 
degli oligo in cellule di mioblasti primari derivati da biopsie di donatori sani. 
Successivamente  gli  stessi  oligonucleotidi  sono  stati  impiegati  per  trattare  le 
cellule dei pazienti con la mutazione. 
Le  cellule  sono  state  trasfettate  con  diverse  quantità  di  AO,  per  saggiare 
eventuali  differenze  nei  prodotti  trascritti  e  sulla  eventuale  tossicità  del 
trattamento. 
Successivamente alla trasfezione sono state effettuate delle RT-PCR da cui si è 
andato a vedere la presenza o meno dello skipping. 
Il disegno degli AO per le cellule sane non ha sempre riscontrato lo stesso effetto 
in cellule di paziente, anzi, tutt’altro. Si è visto che le mutazioni presenti nei 
pazienti  portano  spesso  ad  effetti  diversi  sui  prodotti  di  skipping  rispetto  ai 
controlli  sani,  convalidando  la  nostra  ipotesi  che  un  disegno  specifico  su 
sequenze  non  mutate  possa  non  essere  terapeuticamente  valido  per  le 
mutazioni di alcuni pazienti. 
 INTRODUCTION 
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INTRODUCTION 
Duchenne Muscular Dystrophy (DMD) is the most common X-linked recessive 
disease  with  an  incidence  of  1  in  3,500  male  newborns.  The  pathogenesis 
includes progressive degeneration of skeletal muscle and muscular weakness. 
Regeneration of  fibers becomes less frequent as the disease progresses and 
muscles are eventually replaced by adipose and connective tissues, accounting 
for  the  pseudohypertrophic  muscles.  Patients  are  usually  confined  to  a 
wheelchair by the age of 11, and death from respiratory or cardiac failure is 
common in the late teens to early 20s (Wells et al., 2002). 
The  Becker  Muscular  Dystrophy  (BMD,  also  known  as  Benign 
pseudohypertrophic Muscular Dystrophy) is the allelic form of DMD and has a 
milder  clinical  course  and  a  slower  disease  progression  than  in  Duchenne 
patients.  BMD  has  been  estimated  to  occur  approximately  one-tenth  as 
frequently as DMD, with an incidence of 3-6 per 100,000 newborns. The majority 
of BMD patients initially experience difficulties between 5 and 15 years of age, 
although onset in the 3rd or 4th decade, or even later, may occur. By definition 
the  affected  patients  remain  ambulant  until  16  years  of  age  or  later,  thus 
allowing the clinical distinction from patients with DMD. Patients with BMD have 
a reduced life expectancy, but the majority of patients survive into at least the 
4th or 5th decade. 
Both types of dystrophies are the results of mutations in the DMD gene that 
codes for the dystrophin protein. 
The DMD gene, protein structure and functions 
Discovered  in  the  mid-eighties  (Monaco  et  al.,  1986),  the  DMD  gene  is  the 
longest known human gene, covering 2.4 megabases at locus Xp21; it represents 
0.08% of the whole human genome and 1.5% of the X chromosome. The primary 
transcript measures about 2,400 kilobases and takes 16 hours to be transcribed 
(Tennyson et al., 1995). However, 99.4% of the gene for dystrophin is made of 
large  introns  and  the  coding  sequence  includes  79  exons  that  form  a  14  kb 
mature mRNA. There are 7 known alternative transcripts, comprising three full-
length ones that have the same number of exons but which are derived from 
three independent promoters in brain, muscle, and Purkinje cerebellar neurons 
(Figure 1 A). These three promoters consist of unique first exon spliced to a 
common set of 78 exons (Figure 1 B) and the names in each case refer to the 
major but not exclusive sites of expression; all three mRNAs code for a so-called 
full-length protein isoforms (427 kDa). In addition, dystrophin gene codes for 4 INTRODUCTION 
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shorter  isoforms,  generated  through  alternative  splicing  events.  These  splice 
variants,  which  commonly  occur  in  a  tissue-specific  way,  are  formed  both 
through the exclusion of some exons (exon skipping) and by subversion of the 
reciprocal order of exons (exon scrambling (Muntoni et al., 2003). 
 
Figure 1 A: Genomic organisation of the dystrophin gene, located in Xp21. The black vertical lines represent 
the 79  exons of the  dystrophin gene distributed over about 2.5  million bases.  The arrows  indicate  the 
various  promoters:  in  particular  are  brain  (B),  muscle  (M),  and  Purkinje  (P)  promoters.  B:  The  domain 
composition of the various dystrophin proteins is indicated. (Muntoni et al., 2003) 
The full-length dystrophin is a member of the  -spectrin/ -actinin protein family, 
containing four distinct regions identified by sequence homologies and binding 
capabilities with several sarcolemmal/cytoskeletal proteins (see below) (Blake et 
al., 2002). 
￿ Actin-binding domain: the amino-terminal 220 amino-acids of dystrophin, as 
well  as  utrophin  and  invertebrate  dystrophins  (see  below)  show  clear 
homology to well known actin-binding regions of the spectrin and  -actinin 
families. The amino-terminal domains of dystrophin and utrophin have been 
shown by a variety of methods to bind filamentous actin with affinities below 
micromolar range and with marked preference for “non-muscle” forms of 
actin (Figure 3 B). 
￿ Central  rod  domain:  more  than  70%  of  the  protein  length  consists  of  a 
repeated motif similar to the triple helical repeats of spectrin, which is why 
this domain is also called “spectrin-like”. These  -helical coiled-coil repeats, INTRODUCTION 
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which are interrupted by four proline-rich hinge regions , are thought to give 
the molecule a flexible rod-like structure similar to  -spectrin. 
￿ Cysteine-rich domain: the fourth proline-rich hinge is placed between the rod 
domain and a highly conserved constellation of motifs that constitutes a key 
feature  for  the  dystrophin/dystrobrevin  family.  The  region  comprises  the 
following: a WW domain named after its two conserved tryptophan residues 
(it usually binds proline-rich motifs), an EF hands (a helix-loop-helix structural 
domain found in a large family of calcium-binding proteins that consists of 
two  alpha  helices  positioned  roughly  perpendicular  to  one  another  and 
linked by a short loop region that usually binds calcium ions) and a ZZ domain 
(a  highly  conserved  and  widespread  zinc-binding  motif  first  identified  in 
dystrophin/utrophin and the transcriptional co-activator CBP) (Ponting et al., 
1996). The structure of this region reveals a compact entity, with the WW 
domain and the EF hands intimately packed. Functional studies show that the 
cysteine-rich domain mediates the interaction between dystrophin and the 
intracellular tail of  -dystroglycan, the latter’s PPPYVP motif binding to the 
WW domain; EF hand region increase the affinity of the WW domain cradling 
the site of interaction with  -dystroglycan (Rentschler et al., 1999). Recently 
it  has  been  shown  that  ZZ  domain  is  a  second  dystroglycan-binding  site 
between  dystrophin/utrophin  and  dystroglycan  in  addition  to  the  WW 
domain mediated interaction with the extreme C-terminus of  -dystroglycan. 
This region is likely to be distinct from the well-characterized PPPYVP site due 
to its inability to compete for binding purified  -dystroglycan. This additional 
binding site  further  stabilizes  the  -dystroglycan–WW  domain  interaction, 
which  itself  is  supported  by  the  EF  hand  region,  and  explains  why  the 
complete WW–EF–ZZ region appears to be required for full binding activity 
(Hnia et al., 2007). The generally accepted name is something of a misnomer, 
as only five of the fifteen cysteines (in human dystrophin) that give the region 
its name are highly conserved, four of these being metal ligands in the ZZ 
domain (Roberts, 2001). 
￿ The carboxyl-terminal domain:  the COOH terminus of  dystrophin contains 
two polypeptide stretches that are predicted to form  -helical coiled coils 
similar to those in the rod domain. This domain has been named the coiled 
coil (CC) domain. Approximately 3-5% of proteins have coiled-coil regions. 
Coiled coils are well-characterized protein interaction domains. The CC region 
of dystrophin forms the binding site for dystrobrevin and may modulate the 
interaction  between  syntrophin  and  other  dystrophin-associated  proteins 
(Blake et al., 2002) (Figure 2). The first half of the C-terminal domain interacts INTRODUCTION 
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with the ZZ domain, strengthening its binding to the  -dystroglycan (Hnia et 
al., 2007). 
 
Figure 2 Protein interactions at the COOH terminus of dystrophin. (Blake et al., 2002) 
All  members  of  the  dystrophin  family  appear  to  be  membrane-associated. 
Vertebrate  dystrophin  is  located  at  the  cytoplasmic  membrane  of  skeletal, 
cardiac and smooth muscle cells and at the central nervous system (CNS) in a 
subset  of  postsynaptic  neurons  (in  cerebral  cortex,  hippocampus,  and 
cerebellum).  Shorter  forms  of  dystrophin,  generated  by  alternative  promoter 
usage, are variously expressed: Dp260 is expressed in high concentrations in the 
retina, where it coexists with the full-length brain and muscle isoforms; Dp140 is 
expressed in brain, retina, and kidney tissues; Dp116 is only expressed in adult 
peripheral nerves at the outer surface of Schwann cells. Dp71 is detected in most 
non-muscle tissues including brain, retina, kidney, liver, and lung and is present 
in cardiac but not skeletal muscle (Muntoni et al., 
2003). 
Muscular dystrophin is part of a subsarcolemmal 
protein  assemblies  that  circumferentially  align  in 
register with the Z-disk of peripheral myofibrils and 
physically couple force-generating sarcomeres with 
the  sarcolemma  in  striated  muscle  cells.  This 
lattice, called costamere (Figure 3 A), may function 
to  laterally  transmit  contractile  forces  from 
sarcomeres  across  the  sarcolemma  to  the 
extracellular matrix and ultimately to neighbouring 
muscle  cells.  Lateral  transmission  of  contractile 
force  would  be  useful  for  maintaining  uniform 
sarcomeres  length  between  adjacent  actively 
Figure  3  A:  costameres  structures
coupling  myofibrils  to  sarcolemma
in periodic register with Z-disks. 
B:  sarcolemma  stained  with  Ab  to
-actin  to  reveal  the  costameric
cytoskeleton. (Ervasti, 2003) INTRODUCTION 
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contracting and resting muscle cells comprising different motor units within a 
skeletal muscle. It is also logical that the sites of lateral force transmission across 
the sarcolemma would be mechanically fortified to minimize stress imposed on 
the  relatively  labile  lipid  bilayer.  Other  results  have  long  suggested  that 
costameres  may  coordinate  an  organized  folding,  or  “festooning”  of  the 
sarcolemma,  which  again  may  minimize  the  stress  experienced  by  the 
sarcolemmal bilayer during forceful muscle contraction or stretch (Ervasti, 2003). 
Shortly after identification of the DMD gene and dystrophin, it was shown that 
dystrophin could be tightly associated to at least 10 (trans)membrane proteins 
(Campbell et al., 1989). Since these proteins are co-localised with dystrophin at 
the sarcolemma, co-purified with dystrophin in stoichiometric amounts through 
several purification steps, and were diminished in biopsies from DMD patients 
and muscle of the murine dystrophin-deficient model (Ervasti et al., 1990), it was 
concluded  that  dystrophin  functioned  as  part  of  a  larger,  hetero-oligomeric 
glycoprotein  complex  (Figure  4)  that  may  serve  to  stabilize  the  sarcolemma 
against the repetitive stress imposed during muscle contraction. 
 
Figure 4 Dystrophyn interaction with DAPC at the sarcolemma membrane. (Nowak et al., 2004) 
Dystrophin  and  its  tightly  associated  proteins  were  collectively  named  the 
Dystrophin-associated  Glycoprotein  Complex  (DGC  or  DAPC)  (Campbell  et  al., 
1989). A 156 kDa subunit presenting an extensive glycosylation, in addition with 
a 43kDa subunit, make a very tight association to dystrophin, which is why the 
subunits were renamed  - and  -dystroglycan, respectively. These make up the 
core of the DGC, establishing the transmembrane link between laminin-2 and 
dystrophin.  Interestingly,  their  glycosylation  patterns  are  developmentally 
regulated and largely correlate with the diversity of binding partners in different 
tissues  (Winder,  2001).  The  characterization  of  the  genes  encoding  the 
dystrobrevins and syntrophins (respectively the 88 kDa and 59 kDa dystrophin-INTRODUCTION 
 
16 
 
associated proteins) greatly benefited from comparative investigations into the 
molecular  composition  of  the  mammalian  neuromuscular  junction  (NMJ)  and 
electric organ of Torpedo californica, which preceded the discovery of dystrophin 
(Wagnera et al., 1993). Dystrobrevins and syntrophins are cytoplasmic proteins 
that bind directly to each other and to sequences within the carboxy-terminal 
domain of dystrophin. While syntrophins are thought to function as modular 
adaptors  that  anchor  ion  channels  and  signaling  molecules  to  the  DGC,  no 
myopathy is associated with syntrophin ablation in mice (Kameya et al., 1999). In 
contrast,  knockout  of  -dystrobrevin  results  in  a  progressive  myopathy, 
suggesting an important role in DGC function (Grady et al., 1999). Distinct but 
related genes encode the  -,  -,  - and  -sarcoglycan. The sarcoglycans are all 
single pass transmembrane proteins that co-assemble into a stable tetrameric 
complex.  While  its  function  is  not  fully  understood,  the  sarcoglycan  complex 
appears  to  strengthen  interaction  of  -dystroglycan  with  -dystroglycan  and 
dystrophin. Importantly, mutations in individual sarcoglycan genes lead to loss of 
the  entire  sarcoglycan  complex  (Ozawa  et  al.,  2005).  The  25  kDa  dystrophin 
associated  protein,  named  sarcospan,  is  also  stably  associated  with  the 
sarcoglycan  complex.  However,  no  human  myopathy  has  been  linked  to 
mutations in the sarcospan gene and ablation of sarcospan in mice caused no 
muscle phenotype. Finally,  -dystrobrevin has been shown to directly interact 
with the sarcoglycan complex, which raises the possibility that the myopathy 
accompanying  -dystrobrevin  ablation  may  arise  from  destabilization  of  an 
indirect linkage between dystrophin and the sarcoglycan complex (Ervasti, 2007). 
Phylogenetics: 
Dystrophin is now recognized as the founder member of a protein superfamily 
with  representatives  throughout  the  animal  kingdom.  The  ~70-kDa  signature 
structure of this family is the cysteine-rich domain followed by the coiled-coils 
region (Roberts, 2001) (Figure 5). 
 
Figure 5 Phylogenetic tree of the dystrophin/dystrobrevin family, inferred from a tree constructed using 
sequences of the cysteine-rich and carboxy-terminal domains. (Roberts, 2001) INTRODUCTION 
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The  superfamily  includes  various  types  of  proteins  structurally  and/or 
functionally related to dystrophin: 
￿ Utrophin: the utrophin gene (chromosome 6 in humans, 10 in mice) has the 
almost identical exon-intron organization than the DMD gene, the protein’s 
structure is the same from NH to COOH terminus and several promoters with 
shorter  isoforms  have  been  described;  utrophin  and  dystrophin  are  very 
likely  paralogs  that  arose  by  duplication  during  vertebrate  evolution. 
Utrophin expression is high during embryonic development but declines in 
adult skeletal muscle and is limited to the Neuromuscular Junctions (NMJ) 
and  myotendinous  junctions  in  normal  adult  skeletal  myofibres;  in  early 
normal  development,  both  dystrophin  and  utrophin  are  found  at  the 
sarcolemma of muscle fibres, but at birth utrophin is confined to the NMJ 
(Hirst et al., 2005). Some differences between utrophin and dystrophin actin 
binding  have  been  identified:  on  one  hand,  utrophin  lacks  the  additional 
actin-binding  activity  associated  with  the  dystrophin  rod  domain;  on  the 
other  hand,  the  NH  terminus  of  utrophin  contains  a  short  extension  not 
found in dystrophin which contributes to its affinity for actin (utrophin NH-
terminal fragments thus bind cytoskeletal  -actin more strongly in vitro than 
dystrophin). The primary  structures of the  COOH termini  of  utrophin and 
dystrophin are also very similar, and this suggested that utrophin too might 
be able to bind members of the DGC. The similarities of structure and binding 
partners  between  dystrophin  and  utrophin  have  raised  the  possibility  of 
some functional redundancy between the two proteins but clear functional 
roles for utrophin remain unclear (Blake et al., 2002). 
￿ DRP2: the dystrophin related protein 2 (DRP2) is a further paralogue that 
retains only two of the spectrin repeats. Expression is largely confined to 
punctuate structures in the CNS and patches between the Cajal bands of 
Schwann cells in the Peripheral Nervous System (PNS). Its role in the CNS is 
unknown,  but  in  the  PNS  DRP2  interacts  with  L-periaxin  via  its  spectrin 
repeats (Jin et al., 2007). 
￿ Dystrobrevin:  dystrobrevins  are  a  family  of  dystrophin-related  and                    
-associated  proteins  comprising  alpha-dystrobrevin  ( -DB)  and  beta-
dystrobrevin ( -DB), both of which exist as multiple isoforms. There is also a 
recently  discovered  new  gene,  called  -dystrobrevin,  found  to  be  distinct 
from  - and  -DB. In adult tissues,  -dystrobrevins have been characterized 
primarily as a component of the DGC in skeletal muscle cells.  -dystrobrevin 
is  considered  to  be  a  non-muscular  protein,  which  is  abundant  in  brain, 
kidney, lung and liver. Dystrobrevins interact with proteins involved in signal 
transduction (e.g.,  -dystrobrevins that bind neuronal nitric oxide synthase INTRODUCTION 
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(nNOS)  and  voltage-gated  Na+  channels).  The  specific  space-temporal 
expression  profiles  during  mouse  embryogenesis  also  suggest  a 
developmental role for dystrobrevins. Both proteins lack the long N-terminal 
extension of dystrophins but contain homology with the cysteine-rich and 
carboxy-terminal domains of dystrophin and utrophin (Rees et al., 2007). 
￿ Dystrotelin: in the past few years studies has shown the existence in most 
vertebrate genomes of exons encoding a novel, extremely divergent, possible 
member  of  the  dystrophin/dystrobrevin  family.  This  protein,  called 
dystrotelin,  shows  significant  similarity  to  dystrophin  (30%  identity,  49% 
similarity) and dystrobrevin (30% identity, 46% similarity) over the first 270 
amino acids, corresponding roughly to the EF hands and ZZ domain. As there 
is 32% identity, 53% similarity between dystrophin and dystrobrevin over the 
same region, the three families of proteins appear to be equally related to 
each other. Further studies are required to better understand the function of 
dystrothelins  and  to  resolve  the  trichotomy  of  dystrophin/dystrobrevin 
superfamily (Jin et al., 2007). 
 
Figure 6 Phylogenetic tree with the unresolved point of divergence between dystrophins, dystrobrevins and 
dystrotelins. Phylogenetic distance is represented by the horizontal axis only. (Jin et al., 2007) 
The  evolution  of  the  superfamily  dystrophin/dystrobrevin  (Figure  6)  likely 
originated from a single ancestor (non-metazoan) with a gene containing all the 
signature structural elements still present in most contemporary representatives. 
Such  ancestral  protein  probably  functioned  as  a  homodimer.  Before  the  last 
metazoan ancestor, a duplication gave rise to the dystrophin and dystrobrevin INTRODUCTION 
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genes.  This  is  the  situation  in  most  existing  metazoans  (including  the 
cephalochordate  amphioxus).  In  vertebrates  a  series  of  further  duplications 
occurred;  the  first  gave  rise to DRP2 in the  dystrophin branch  and  a second 
resulted in the separate dystrophin and utrophin genes (Roberts, 2001). On the 
dystrobrevins branch a duplication gave rise to  - and  -dystrobrevin’s common 
ancestor, as well as to the  -dystrobrevin recently discovered gene (Jin et al., 
2007). Invertebrates, as it is the case with many gene families, have a simpler 
repertoire of proteins; all metazoans so far examined (including, for example, 
Drosophila melanogaster and  Caenorhabditis elegans)  have  single  dystrophin- 
and dystrobrevin-like molecules. 
The  possession  of  distinct  dystrophin and  utrophin molecules is a  specifically 
gnathostome trait, arising from a duplication that occurred after our divergence 
from cyclostomes. The duplication which gave rise to the DRP2 gene occurred 
before this point in time, but after the divergence from amphioxus; thus the last 
common  ancestor  of  cyclostomes  and  gnathostomes  had  two  dystrophin-like 
molecules, namely DRP2 and a common ancestor of dystrophin and utrophin. 
Cyclostomes are likely to have subsequently lost their DRP2 gene. 
Animal models: 
Mutations on DMD gene have been reported in many vertebrates, as well as 
mutations in the hortologues genes of invertebrates, but only a few of them 
have  been  studied.  Vertebrates  (mammalian)  are  the  main  animal  models 
currently used, although interesting features of invertebrates (see below) make 
them suitable for future approaches. 
Mdx mouse: 
The dystrophin deficient mdx mouse is the most widely used model of DMD; its 
small size and ease of husbandry make it a cost-effective model to investigate 
aspects of pathogenesis and treatment. The mdx mouse was first described by 
Bulfield and colleagues in 1984 when they noted mice with very high serum level 
of the muscle enzyme creatine kinase, indicative of muscle damage (this is also 
one of the main markers for DMD diagnosis). With the identification of the DMD 
gene  and  its  protein  product  the  mdx  mouse  was  confirmed  as  having  a 
dystrophin deficiency, which was subsequently shown to be due to a nonsense 
point mutation in exon 23. Mdx mice develops a severe myopathy at 2-3 weeks 
of age, which continues for approximately 5 to 6 weeks. After this peak the rate 
of degeneration slows down and then continues for the lifespan of the mouse, as 
shown by a continued raised level of serum creatine kinase. The majority of the 
limb musculature does not undergo major fibrosis and loss of function so that INTRODUCTION 
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the lifespan and general mobility of the mdx mouse is relatively normal, although 
there is a marked deterioration in older animals (Lefaucheur et al., 1995). This 
mild phenotype has lead to the mdx mouse being criticized as a poor model of 
DMD. There are many theories as to why the mdx mouse is less severely affected 
by the dystrophin deficiency compared to DMD patients, including differences in 
muscle  regenerative  capacity,  increased  utrophin  expression,  effects  of  size 
and/or the quadrupedal stance. However, one muscle, the diaphragm, is severely 
affected by the dystrophin deficiency showing dramatic fibrosis and fibres’ loss. 
Other tonically active muscles, such as the soleus, also show marked fibrosis in 
the old mdx mouse (Wells et al., 2005). 
A series of mdx variants (termed mdx2Cv, mdx3Cv, mdx4Cv, and mdx5Cv) were 
derived from mice treated with the chemical mutagen N-ethyl-nitrosourea. The 
main differences from the original mdx strain consist of larger variation in size, 
pseudomyotonia  and  some  ﬁbrosis  detected  in  the  hearts  of  mdx2Cv  and 
mdx3Cv at the age of 4 weeks. The mdx3Cv strain also displays an abnormal 
breeding phenotype with reduced neonatal survival. The mdx4cv strain present 
lower frequency of revertant fibers (Willmann et al., 2009). 
Canine models: 
Spontaneous mutations of the dystrophin gene resulting in X-linked muscular 
dystrophy  have  been  identified  in  several  breeds  of  the  domestic  dog:  the 
Golden  Retriever  (Cooper  et  al.,  1988),  the  German  short-haired  pointer 
(Schatzberg et al., 1999) and the Beagle (Shimatsu et al., 2003). 
The golden retriever muscular dystrophy (GRMD) is the best characterized dog 
model; the disease results from a single base pair change in the 3’ consensus 
splice site of intron 6, leading to skipping of exon 7 and alteration of the reading 
frame in exon 8, which creates a premature stop codon (Sharp et al., 1992). 
Unlike the dystrophin-deficient mdx mouse, GRMD dogs suffer from a rapidly 
progressing fatal disease similar to DMD. There is, however, a large variation in 
disease  severity  as  some  pups  survive only  for  a  few  days,  while  others  are 
ambulant for months or even years. Incomplete muscle repair in GRMD results in 
progressive weakness and gait abnormalities at the age of 6-9 weeks, followed 
by  muscle  atrophy,  fibrosis  and  severe  contractures  by  6  months.  The  dogs 
become less active than non-affected littermates at about 9 months of age. At 
this time, their gait is still uncoordinated and their limbs are abducted. Severely 
affected dogs have difficulties to rise and can walk only a few steps. At the age of 
12  months,  pharyngeal  and  oesophageal  dysfunctions  start  to  develop  and 
respiratory capacity is decreased. Kyphosis develops by the 6
th month of age. 
Moreover,  as  seen  in  DMD  patients,  GRMD  dogs  display  selective  muscle INTRODUCTION 
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involvement although the pattern differs from that seen in humans. Myocardial 
involvement is much more evident in the golden retriever than in other animal 
models, matching very closely the cardiac complications often encountered in 
DMD patients (Moise et al., 1991). 
Beagle dogs were mated with an affected golden retriever to obtain a breed of a 
smaller size, which is an advantage for some research purposes. One of these 
strains has been established in Japan (Canine X-linked Muscular Dystrophy in 
Japan CXMDJ). The survival rate of these beagle dogs is increased compared to 
golden retriever. In general, large breed dogs develop more severe clinical signs 
than small breed dogs. The diaphragm muscle is affected shortly after birth while 
in  limb  muscles  abnormalities  become  evident  only  after  2  months  of  age. 
Cardiac involvement in the CXMDJ dogs is milder and has a slower progression 
than that described for GRMD dogs (Shimatsu et al., 2005). 
Feline models for DMD: 
The dystrophic cat, which lacks approximately 200 kb of the dystrophin gene, is 
affected by ‘‘Hypertrophic Feline Muscular Dystrophy” (HFMD) (Winand et al., 
1994). In HFMD the levels of creatine kinase in the blood increase by the age of 
4-5 weeks, whereas muscle involvement becomes apparent only at the age of 
10-14 weeks. The name of the disorder reflects the development of extensive 
muscle hypertrophy and affected animals eventually die due to compression of 
the oesophagus by the hypertrophied diaphragm or because of impaired water 
intake  caused  by  glossal  hypertrophy.  Histological  analysis  has  revealed  the 
presence of local foci of necrosis and regeneration but no signs of fibrosis were 
seen. Although cardiac failure is rare, hearts are hypertrophic in 9-month-old 
cats. Thus, the pathology of HFMD cats does not resemble DMD as closely as the 
GRMD  dog  because  it  lacks  the  hallmarks  of  generalized  muscle  wasting 
(Willmann et al., 2009). 
Other vertebrate models of DMD: 
The  relative  ease  and  reduced  cost  of  generating  genetic  mutants  in  the 
zebrafish  (Danio  rerio)  compared  to  the  mouse,  as  well  as  the  rapid  muscle 
development at a time when the embryo is effectively transparent, has led to 
this species being investigated as an animal model of DMD (Wells et al., 2005). 
Zebrafish are attractive as models of myopathy because they have high skeletal 
muscle  content  and  express  orthologues  of  most  human  DGC  proteins  with 
similar  membrane  localization.  While  gene-targeting  technologies  are  not 
currently  available,  equivalent  experiments  can  be  carried  out  using 
oligonucleotide analogues (morpholinos) that disrupt the translation of specific 
mRNA transcripts. This technique has been used to create dystrophin-deficient INTRODUCTION 
 
22 
 
zebrafish that have an unstable DGC, bent morphology and lower activity (Guyon 
et al., 2003). 
Invertebrate models: 
The two invertebrate “workhorses” widely used in genetics research, Drosophila 
melanogaster and Caenorhabditis elegans, have also been used as animal models 
of DMD. Most of the work with the invertebrates has been devoted to identifying 
the  homologous  genes  for  dystrophin  and  DAG  and  understanding  their  role 
using various mutants. Conservation of sequence and gene structure shows the 
fundamental importance of many of these genes in maintaining muscle function. 
The muscles of C. elegans have a sarcomeric structure and similar proteins to 
mammalian striated muscle, despite their being formed by single mononucleated 
cells.  Mutation  of  the  dystrophin-like  gene  (dys-1)  leads  to  a  progressive 
locomotor defect due to widespread destruction of the muscles of the body wall. 
C. elegans has been used to examine genes that can modify the effects of the 
dystrophin  deficiency  and  has  recently  been  used  to  screen  a  range  of 
compounds for their ability to reduce muscle degeneration. This latter showed 
that although none of the drugs tested reduced the locomotor impairment, the 
corticosteroid prednisone (which is already in DMD support treatment) reduced 
the number of abnormal cells, thus confirming the potential utility of this model. 
As the authors noted, the fact that C. elegans has no vertebrate-like immune 
system and does not have an inflammatory response, strongly suggests that a 
beneficial effect of prednisone could also be exerted directly on the muscles 
(Wells et al., 2005). 
Mutations and pathogenesis in DMB/BMD: 
Patients with DMD have very little or no detectable dystrophin whereas BMD 
patients have dystrophin of altered size and/or in diminished quantity. However, 
etiopathogenesis may be more complex than a simple loss of dystrophin. Studies 
have shown that several of the glycoproteins that interact with dystrophin are 
also absent in these disorders (Ervasti et al., 1990) and they have been suggested 
to be directly involved with increased calcium  influx in the  dystrophic fibers. 
Thus, the loss of dystrophin may be just the first of many steps that ultimately 
lead to muscular dystrophy. 
Approximately  60  to  65%  of  the  mutations  that  cause  DMD/BMD  are  large 
deletions in the dystrophin gene. Their distribution along the gene show that 
they are no randomly distributed and occur primarily in two “hot spots”: one in 
the rod domain (~80%) and one near the 5’ end (~20%) of the gene. The 200-kb 
region  covering  intron  44,  exon  45,  and  intron  45  is  the  major  deletion INTRODUCTION 
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breakpoint region of the gene. Most of the larger deletions initiate at the 5’ end 
of  the  gene.  Initial  studies  showed  no  immediate  correlation  between  the 
size/location of the deletion and the severity of the phenotype. Furthermore, 
sequences deleted in DMD patients overlapped with deletions in BMD patients 
(Figure 7 A). The existence of the two allelic forms was then explained by the so-
called “reading frame hypothesis” (Monaco et al., 1988), i.e., it was proposed 
that  if  a  deletion  disrupts  the  translational  reading  frame  of  the  dystrophin 
mRNA then a C-terminally truncated, non-functional protein will be synthesized, 
resulting in  the  more  severe  DMD. On  the  other  hand,  in  BMD  patients  the 
deletion maintains the translational reading frame and thus a semi-functional 
protein  is  produced.  The  hypothesis  explains  the  phenotypic  differences 
observed  in  ~90%  of  the  DMD/BMD  cases,  including  one  of  the  largest  rod-
domain deletions identified (35 exons) in a mild BMD patient. Exceptions to the 
reading frame hypothesis (~8-9%), involving an out-of-frame exon deletion with 
a BMD phenotype (for example exon 3 to 7 deletions) (Malhotra et al., 1988), 
have  been  explained  with  an  alternate  splicing  mechanism  or  a  new  cryptic 
translational start site. A small number of DMD patients with in-frame deletions 
have also been identified. The more severe phenotype in these patients may be 
due to the overall effect of the deletion on the protein conformation or be the 
result of message instability. 
Some  phenotypic  variability  occurs  in  patients  who  share  identical  gene 
deletions.  The out-of  frame deletion of  exon 45, one of the most commonly 
observed DMD deletions, has also been associated with BMD phenotypes (Prior 
et al., 1997). Some genetic variability might be due to modifier genes that affect 
splicing or other molecules involved in destruction of damaged muscle fibers, 
muscular regeneration, or in the cellular response to different hormones. 
The DMD gene has an unusually high mutation rate, between 10
-4 and 10
-5 (van 
Essen et al., 1992). This could be due to the large gene size, particularly the very 
large  introns,  but  other  factors  are  also  likely  involved.  For  example,  the 
observed non-random deletion pattern may reflect domain-associated variation 
in chromosomal stability (Prior et al., 2005); besides, complications related to the 
maintenance of replication, correct transcription and proper splicing of such a 
large gene might play an important role. Partial gene duplications have been 
revealed  in  ~5  to  10%  of  patients  (Hu  et  al.,  1990).  Unlike  the  deletion 
distribution, duplications occur more frequently at the 5’ end of the gene than in 
the central region (Figure 7 B). 
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Figure 7 Distribution of deletions (A) and duplications (B) in the dystrophin gene in DMD and BMD patients. 
Each bar represents a mutation observed in a patient. The number to the right of the bar indicates the 
number of independent patients sharing mutation of the same exon. (Prior et al., 2005) 
The deletion and duplication distribution has been  demonstrated in different 
populations and ethnic groups. Out-of-frame duplications in DMD patients and 
in-frame duplications in BMD patients have been observed, suggesting that the 
reading frame hypothesis also holds true for duplications. As expected, there are 
also  reports  of  small  mutations  –  point  mutations,  small  deletions  and 
duplications  –  found  in  DMD  and  BMD  patients  without  large  deletions  or 
duplications (Prior et al., 1995). Missense mutations are rare in the dystrophin 
gene,  even  amongst  BMD  patients.  Several  base  changes  causing  significant 
amino acid substitutions have been reported in the dystrophin gene, but the 
majority of these resulted to be polymorphic changes. DMD missense mutations 
described in exons 3 and 16 have supported the important role of an intact actin-
binding domain and of a little portion of the rod domain for dystrophin function 
(Prior et al., 2005) (Wang et al., 2000). INTRODUCTION 
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Despite  the  almost  twenty  years  passed  from  the  isolation  of  DMD  gene, 
comprehensive understanding of the mechanism leading from the absence of 
dystrophin to the muscular degeneration is still lacking. In patients affected by 
DMD,  muscle  biopsy  characteristically demonstrates  necrotic  or  degenerating 
muscle fibers, often observed in clusters. These necrotic fibers are surrounded by 
macrophages and CD4+ lymphocytes. Small immature centrally nucleated fibers 
are also observed, reflecting the ongoing muscle regeneration that in the early 
phases  of  the  disease  leads  to  a  balance  between  necrotic  and  regenerative 
processes. As time goes by, though, the regenerative capacity of the muscles 
becomes exhausted and muscle fibers are gradually replaced by connective and 
adipose tissue (Bockhold et al., 1998). The manifestations of Duchenne muscular 
dystrophy  are  hence  considered  to  be  the  result  of  an  imbalance  between 
muscle fiber necrosis and myoblast regeneration. 
Early  descriptions  of  muscle  histopathology  (with  focal  lesions  in  the  plasma 
membrane  overlying  wedge-shaped 
defects  in  muscle  fibers  known  as 
“delta  lesions”)  and  raised  levels  of 
muscle  enzymes  in  Duchenne 
muscular  dystrophy  patients  have 
long  been  interpreted  as  reflecting 
excessive  fragility  of  the  muscle 
fibers.  The  discovery  of  dystrophin 
and  other  members  of  the 
dystrophin-associated  glycoprotein 
complex  scaffolding  supported  the 
view that the absence of one of these 
proteins  could  compromise  the 
muscle  membrane  integrity  of  the 
fibers,  particularly  after  sustained 
contractions. 
Documentation  of  calcium 
accumulation and of hypercontracted 
fibers in muscle biopsies of Duchenne 
muscular  dystrophy  patients  has  led 
to  the  investigation  of  the  possible 
role  of  calcium  in  Duchenne 
muscular dystrophy. Increased influx 
through a dystrophin-deficient membrane has been demonstrated (Franco et al., 
1990).  This  influx  seems  to  occur  mostly  through  mechanosensitive,  voltage-
Figure  8  Proposed  pathophysiology  of
dystrophinopathies. (Deconinck et al., 2007) INTRODUCTION 
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independent calcium channel. However, despite increased influx, low to normal 
calcium concentration can be maintained within the fiber cytosol, reflecting the 
robustness of the calcium homeostatic mechanisms. Still, if mechanical stress 
induces microlesions in the fiber membrane high influx of extracellular calcium 
inevitably occurs, overriding the capacity to maintain physiologic cytosolic Ca
2+ 
concentration.  Sustained  increase  in  cytosolic  calcium  concentration  leads  to 
activation  of  proteases,  particularly  calpains,  resulting  in  the  destruction  of 
membrane  constituents  that,  in  turn,  will  increase  calcium  entry.  Excessive 
calcium  may  then  lead  to  cell  death  (Figure  8).  In  line  with  the  calcium 
hypothesis,  several  treatment  trials  with  different  calcium-blockers  (e.g., 
diltiazem)  have  been  tested  in  Duchenne  muscular  dystrophy,  but  have 
demonstrated almost no clinical benefit. On the other hand, overexpression of 
calpastatin (endogenous inhibitor of calpains) has been demonstrated to reduce 
necrosis in mdx  muscle (Deconinck et al., 2007). 
Revertant fibers: 
An interesting phenomenon that occurs in  40% of DMD patients (Fanin et al., 
1995) is the presence of “revertant fibers”. These are defined as centronucleated 
fibers (deriving from regeneration processes) that express dystrophin (Hoffman 
et al., 1990). They represent only a little percentage of all muscle fibers and this 
phenomenon is not limited to humans, but has also been observed in the mdx 
mouse  and  the  CXMD  dog  (Wilton  et  al.,  1997).  Immunofluorescent  analysis 
using a wide group of antibodies specific to the N- and C-terminal regions of 
dystrophin showed that these domains are expressed in revertant fibers (Thanh 
et al., 1995). However, antibodies recognizing portions of dystrophin encoded by 
exons near the mdx mutation (nonsense mutation in exon 23) typically fail to 
detect  the  revertant  dystrophin.  These  studies  therefore  suggested  that 
revertant  fibers  express  dystrophins  that  arise  from  alternatively  spliced  (in-
frame)  transcripts  lacking  both  the  mutant  exon  and  a  variable  number  of 
adjacent exons (Lu et al., 2000). 
Therapeutic approaches for DMD: 
Pharmacological therapies: 
Corticosteroids : 
Prednisolone, prednisone and deflazacort are the only drugs shown to be able to 
delay  the  progression  of  DMD,  while  easing  its  symptoms.  The  specific 
mechanisms by which corticosteroids improve strength in affected patients are 
not  known,  but  various  possibilities  have  been  proposed.  These  include 
alteration of gene regulation in muscle fibers, slowing down of skeletal muscle INTRODUCTION 
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breakdown, decrease in the number of cytotoxic T cells, lowering of cytosolic 
calcium concentrations and increase myogenic repair. Non-randomized studies 
of long-term daily corticosteroids suggest that ambulation may be prolonged by 
up to three to five years and that life expectancy is improved. Corticosteroids 
also appear to have a positive effect on the complications associated with DMD. 
Proteasome inhibitors: 
Bonuccelli  and  coworkers  (Bonuccelli  et  al.,  2003)  explored  the  use  of 
proteasome inhibitors as a therapy for DMD on the premise that, in the absence 
of dystrophin, members of the DGC are degraded through an unknown pathway 
that leads to their reduction in dystrophic muscle. They initially investigated the 
continuous systemic treatment with the proteasome inhibitor MG-132 in mdx 
mice;  other  proteasome  inhibitors  have  then  been  explored,  leading  to 
decreased  damage  of  the  muscle  membrane  and  improved  muscle  integrity. 
These findings corroborate the proposal that protein degradation in dystrophin-
deficient muscle is mediated by the proteasomal pathway and open up a new 
avenue for possible therapeutic approaches. 
Aminoglycoside antibiotics: 
Between 5% and 15% of DMD cases are caused by premature stop codons, and 
so  the  use  of  aminoglycoside  antibiotics  (for  example,  gentamycin  and 
negamycin), which promote translational readthrough of stop codons, has been 
investigated. Despite hopeful results in mdx mice – 6% dystrophin-positive fibers 
(Arakawa et al., 2003); 10–20% of normal dystrophin levels (Barton-Davis et al., 
1999) – no dystrophin expression has been achieved in human studies of DMD 
and  BMD  patients  and  a  replication  of  the  mdx  results  have  not  been 
forthcoming (Dunant et al., 2003). 
PTC124 is a new orally administered drug that promotes ribosomal read-through 
of stop codons and full-length dystrophin expression and decreased CK levels 
with PTC124 has been successfully detected in phase 2 trials. 
The  main  concern  regarding  the  use  of  read-through  stop  codon  drugs  is  of 
course the theoretic risk of a global read-through of physiological stop codons 
(Yiu et al., 2008). 
Utrophin overexpression: 
In the absence of dystrophin, utrophin is upregulated, but not to a level sufficient 
to  compensate  functionally  for  the  loss  of  dystrophin  and  prevent  the 
progression of muscular dystrophy. Increasing the expression of utrophin in the 
muscles of mdx mice by three- to four-fold is sufficient to prevent or dramatically 
reduce muscular dystrophy pathology (Cossu et al., 2007). INTRODUCTION 
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Various factors that increase utrophin expression are being explored, such as 
heregulin and L-arginine, but most are still in the very early stages (Yiu et al., 
2008). 
Transplant of myogenic cells: 
Regeneration in skeletal muscle is driven by its resident population of myogenic 
stem  cells,  termed  “satellite  cells”,  located  between  the  basal  lamina  and 
sarcolemma of mature skeletal muscle fibers. These are considered multipotent 
stem cells, as they not only can enter the myogenic differentiation pathway but 
can also be induced to enter adipogenesis and osteogenesis. Normally quiescent, 
upon activation satellite cells rapidly proliferate and originate large number of 
myogenic precursor cells, named myoblasts. These latter can also be cultured 
and expanded in vitro for several passages. 
In the recent past several different stem cell populations, derived from muscle 
but also from other compartments, have been assayed for their ability to treat 
muscular dystrophy. In order to correct the dystrophic phenotype, transplanted 
cells must fuse to existing, or form new, myotubes. Upon fusion, the contribution 
of genetically  normal  myonuclei  to  the  muscle  myofiber should  result  in  the 
production  of  a  functional  dystrophin  protein.  At  the  same  time,  however, 
transplanted  cells  should  be  able  to  replenish  the  satellite  cell  pool  of  the 
diseased muscles. 
Past experiments involving myoblast transfer to treat DMD (Law et al., 1990) 
failed to show substantial physiological correction of the dystrophic phenotype. 
More recently, different groups have demonstrated that the transplant of a small 
number of freshly isolated (i.e., non expanded in vitro) satellite cells can greatly 
contribute to muscle regeneration in mdx mice (Collins et al., 2005) (Sacco et al., 
2008).  
Other studies have been focused on the use of different stem cells (Figure 9): 
muscle side population (SP) cells (Gussoni et al., 1999), bone marrow derived 
cells (Ferrari et al., 1998), multipotent mesenchymal stem cells (MSCs) (Caplan, 
1991),  muscle  derived  stem  cells  (MDSCs)  (Torrente  et  al.,  2001),  vessel 
associated stem cells (mesangioblasts) (Sampaolesi et al., 2006), embryonic stem 
(ES) (Bhagavati et al., 2005). INTRODUCTION 
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Figure 9 Diversity of myogenic stem cell populations. (Price et al., 2007) 
At present, however, several problems remain to be solved before envisaging a 
cell-based trial in humans. 
 
Gene therapy: 
Gene addition: 
The use of recombinant viral vectors that carry critical regions of the DMD gene 
has  being  explored  since  mid  1990s.    As  only  a  small  transcript  size  can  be 
incorporated into most available vectors, microdystrophin and minidystrophin 
genes  have  been  created,  leading  to  restoration  of  dystrophin  expression  in 
murine and canine models. The main challenges in this form of therapy include 
the  likely  need  for  immunosuppression  and  the  optimization  of  recombinant 
vector delivery to multiple muscle groups. The use of non-viral vectors has also 
been described (Yiu et al., 2008). 
Exon skipping by means of antisense oligonucleotides: 
Antisense  oligonucleotides  (AOs)  can  sterically  inhibit  gene  expression  by 
hybridizing to target RNA sequences at key sites for the pre-mRNA maturation or 
for the translation process (Aartsma-Rus et al., 2007). INTRODUCTION 
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Researchers have hence tried to 
use  AOs  to  redirect  dystrophin 
splicing and exclude one or more 
exon(s)  (exon  skipping)  in  order 
to  restore  the  reading  frame  of 
the mRNA and produce a slightly 
shorter  but  partially  functional 
protein.  In  other  terms,  this 
approach  would  try  to  convert 
DMD  patients  into  their  milder 
counterpart, BMD (Figure 10). 
Normal  occurring  alternative 
splicing  of  dystrophin  pre-mRNA 
in revertant fibers has had a great 
influence  in  exon  skipping 
studies,  suggesting  the  strategy 
of restoring the reading frame. 
AOs used in exon skipping target 
pre-mRNA  sequences  involved  in 
the splicing process, preventing the inclusion of one or more specific exons. 
Acceptor, donor and branch sites should be the obvious target for exon skipping 
(Figure 11 a), but Exonic Splicing Enhancer (ESE) are also common targets (Figure 
11 c). 
AOs for exon skipping are relatively short (13–25 nucleotides) and hybridize (at 
least in theory) to a unique sequence in the total pool of targets present in cells. 
Although  it  is  not  a  complicated  matter  to  synthesize  phosphodiester 
oligonucleotides,  their  use  is  limited  as  they  are  rapidly  degraded  by  the 
intracellular  endonucleases  and  exonucleases,  usually  via  3’ 5’  activity.  In 
addition, the degradation products of phosphodiester oligonucleotides, dNMP 
mononucleotides, may be cytotoxic and also exert antiproliferative effects (Dias 
et al., 2002). For this reason, modified AOs have been widely studied. 
Figure  10  Restoration  of  the  reading  frame  using
antisense  oligonucleotides  (AON).  (Aartsma-Rus  et  al.,
2007)INTRODUCTION 
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Figure 11 a: Conserved motifs at acceptor (5’), donor (3’) and branch site. b: common modes of alternative 
splicing. c: protein interaction of exonic splicing enhancer (ESE). (Cartegni et al., 2002) 
First-generation phosphorothioate modifications used a substitution of a non-
bridging  phosphoryl  oxygen  of  DNA  with  sulphur,  increasing  resistance  to 
nuclease digestion and prolonging half-life (Figure 12 A). Second-generation AOs 
have  then  been  designed,  showing  improved  stability  and  efficacy  thanks  to 
chemically modification of the phosphodiester-linkage, the heterocycle or the 
sugar (Figure 12 B). So far, modifications made to the ribose, and in particular, 
the 2'-position, seem to be the most important in improving the pharmacokinetic 
characteristics  of  second-generation  AOs.  Third  generation  chemical 
modifications  such  as  PNAs  (Peptide  Nucleic  Acids)  and  PMOs 
(Phosphorodiamidate  Morpholino  Oligos)  (Figure  12  C)  promise  further 
improvements (Gleave et al., 2005). INTRODUCTION 
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Figure 12 First, second and third generation AO. (Gleave et al., 2005) 
Successful skipping has been demonstrated in cultured mdx myotube (Wilton et 
al., 1999), the mdx mouse (Lu et al., 2003), and cultured muscle cells derived 
from DMD patients (Aartsma-Rus et al., 2003). Recent investigations into double-
exon  and  multi-exon  skipping  (skipping  of  numerous  successive  exons)  have 
enhanced  the  technique  to  treat  a  greater  number  of  dystrophin  mutations 
(Aartsma-Rus et al., 2004). 
van Ommen and colleagues recently proceeded with the first human trial with 
successful results, by injecting a 2’-O-methyl–modified ribose molecule with a 
full-length  phosphorothioate  backbone  (2OMePS)  into  the  tibialis  anterior 
muscle  (van  Deutekom  et  al.,  2007),  obtaining  17  to  35%  of  dystrophin 
expression. Muntoni and colleagues recently finished a second trial using a PMO 
(Kinali et al., 2009) with dystrophin restoration up to 42%. 
One of the major concern about AOs was that no dystrophin rescue could be 
observed in the heart muscle, but last year Lu and colleagues demonstrated in 
vivo a “nearly total” restoration of functional dystrophin (even in cardiac muscle) 
using  a  peptide-tagged  phosphorodiamidate  morpholino  oligomer  (PPMO)  in 
mdx mice (Wu et al., 2008). 
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AIM OF THE WORK 
Up to now virtually all AO designing procedures for exon skipping in the human 
DMD gene have been tested on normal human cells. There have been recent 
indications that the different genomic re-arrangements (deletion, duplications, 
point  mutations,  etc.)  present  in  patients  could  affect  the  efficiency  of  the 
desired skipping processes, but this aspect has been barely studied so far. In this 
work we hence compared the results obtainable in wild type controls and in 
myoblasts from patients carrying different types of mutations, when using AOs 
designed from the wild type DMD sequence with the currently available software 
tools. INTRODUCTION 
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MATERIALS AND METHODS 
Cell cultures: 
Unless otherwise specified, all cell culture reagents were from Invitrogen™. 
Medium used for cells proliferation was called “aneural medium” (see below for 
composition). 
Biopsies from healthy donors were used to obtain wild type cells (called MCQ), 
these  cells  were  used  to  test  the  AOs  in  a  non  mutated  context.  Muscle 
specimens  were  obtained  from  the  Telethon  biopsy  repository  of  Padua 
(collaboration with Dr. Marina Fanin). Patients’ cells (Table 1), derived with the 
same procedure, were then sent us as frozen cultures by the Telethon Cell Bank 
in Besta Institute in Milan. 
Frozen  biopsies  were  rapidly  thawed  in  a  water  bath  at  37°C,  residual 
dimethylsulphoxide (DMSO) was washed away rinsing biopsies in rich medium 
(70% M199 and 30% FBS) and muscle specimens were incubated in a freshly 
prepared mixture of 80% rich medium plus 20% human plasma (this medium was 
filtered through a dish with 0.22 µm pore directly over the specimens) into a well 
of  a  6  well  plate.  Several  days  after  plasma  clot  formation,  myoblast  cell 
proliferation was observed, muscle specimens were then trimmed into pieces of 
about 1 mm
3 and placed on a new well. Growing cells were fed with aneural 
medium, replaced three times a week. Tissue fragments were repositioned every 
3-4  days  and  cells  were  trypsinized  to  allow  them  to  proliferate  without 
differentiate. 
Aneural medium was composed of: 
- 60 %   Dulbecco's Modified Eagle Medium (DMEM) 
- 20%   M199 
- 20%   Fetal Bovine Serum (FBS) 
- Insulin 10 ng/ml final 
- bFGF   2 ng/ml final      (from PeproTech ©) 
- EGF   10 µg/ml final     (from PeproTech ©) 
FGFs (Fibroblast Growth Factors) are known to be potent regulators of myogenic 
cell proliferation and differentiation. When used in primary muscle culture they 
have been shown to delay, but not inhibit, myoblasts fusion; bFGF in human 
muscle appears to exerts both proliferative and trophic influence (Sheehan et al., 
1999).  
Insulin is a factor for growth and maturation of many types of cells; the addition 
of supra-physiologic doses of insulin promotes differentiation of muscle cells of 
various animal species. MATERIALS AND METHODS 
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EGF (Epidermal Growth Factor) alone was reported to be the most important 
factor  influencing  muscle  differentiation  in  human  satellite  cells  (Ham  et  al., 
1990). 
Interestingly the presence of those three factors can increase the total number 
of cells  while  a combination of only two of them influence only morphology 
(Askanas et al., 1985). 
All media were added with a mixture of antibiotics called PSFG containing: 
- Penicillin   10 U/ml final 
- Streptomycin  0,1 mg/ml final 
- Fungizone   0,8 µg/ml final 
- Gentamycin   0,15 mg/ml final 
Frozen  cells  were  rapidly  thawed  in  a  water  bath  at  37  °C  and  diluted  in 
approximately 5 ml of DMEM before being pelleted with a 10 minutes spin at 
400×g. Cells were resuspended and plated in aneural medium 80% plus 20% of 
macrophage-conditioned medium (MCM). This latter is known contains muscle-
specific growth factor that increase primary myoblast proliferation and enhance 
their  myogenic  differentiation  (Cantini  et  al.,  2002).  Previous  work  has  also 
demonstrated that MCM could be used in cultures of primary myoblasts from 
DMD patients to increase their expandability while preserving their myogenic 
potential (Malerba et al., 2008). 
MCM was obtained from the J774 murine macrophage cell line (Ralph et al., 
1975). Cells were grown in DMEM containing 10% of FBS; when plates were at 
90% confluence, after three rinsing in Phosphate Buffered Saline (PBS, 3.2 mM 
Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH 7.4/0.14 M NaCI, 0.01 
M PO4 Buffer, 0.003 M KCI) cells were re-fed with serum-free medium containing 
0.01  µg/ml  lipopolysaccharide  (E.  coli  LPS,  Sigma-Aldrich®).  After  24  h  the 
medium was removed and, after thorough PBS rinsing, cultures were kept for 72 
more  hours  in  serum-free  DMEM.  The  supernatant  was  then  harvested, 
centrifuged at 400 ×g for 10 min and passed through a 0.22 µm filter to eliminate 
the cellular debris and then stored at -20 °C. 
Transfection: 
Lipofectamine™ 2000, a commercially available cationic lipid formulation from 
Invitrogen, was used for transfections with AOs. Cultures from pates or flasks 
were splitted before confluence and  ~7×10
4 cells were placed in each well of a 
24 multi-well plate. 
When  cells  reached  ~90%  confluence  (and/or  first  observation  of  myotubes) 
growth medium was removed and transfection was carried out in Opti-MEM® I MATERIALS AND METHODS 
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Reduced  Serum  Media,  without  antibiotics  (as  this  reduces  transfection 
efficiency and causes cell death). 
LIpoplexes preparation was carried out by mixing 100 µl of a suspension formed 
by Opti-MEM® and Lipofectamine™ (2 µl per µg of AOs) with a solution of 100 µl 
Opti-MEM®  and  the  indicated  amounts  of  AOs  (indicated  quantities  are  per 
single  well).  Both  the  liposome  and  DNA  solutions  were  first  incubated 
separately  for  5  minutes  in  ice,  then  mixed  together  and  left  for  further  15 
minutes in ice. Per each well, 300 µl of Opti-MEM were added, to reach a total 
volume of 500 µl. Five different AOs amounts were tested (when enough cells 
were available): 600, 300, 100, 50 and 25 nanomoles per well. 
After  24  hours  of  incubation  Opti-MEM®  were  discarded  and  total  RNA  was 
extracted. 
PATIENT IDENTIFICATION 
NUMBER 
TYPE OF MUTATION 
EXON TO BE SKIPPED TO 
RESTORE THE READING FRAME 
4969 Deletion exon 51 50 
4967 Deletion exons 48-52 53 
7547 
Point  mutation  intron  58
(resulting in a deletion of exon 58) 
59 
8566 Deletion exon 12 11 
4445 Deletion exons 46-47 45 
Table 1 
In this study 2’-O-methyl-phosphorothioate modified AOs were used (Figure 13). 
AOs were synthesized to anneal to splicing motifs at the intron-exon boundaries, 
as well as ESE motifs predicted by the web-based application, ESEfinder (Cartegni 
et al., 2003). 
 
 
Figure 13 Structure of AOs used in this study, showing backbone and 2’ modifications. 
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Immunofluorescence analysis: 
Presence and localisation of dystrophin in DMD cells, transfected cells and wt 
control cells. 
Cells were growth over cover slips and then immunofluorescence analysis was 
performed with the following protocol: 
￿ Fix in para-formaldehyde (PFA) 2% in PBS, 10 minutes at room temperature. 
￿ Wash once in PBS for 2 minutes. 
￿ Block with PBS containing 3% Bovine Serum Albumin (BSA) for 45 minutes. 
￿ Wash briefly in PBS. 
￿ Incubate with a rabbit polyclonal antibody against dystrophin (Abcam ©), 
diluted 1:100 in PBS containing 1% BSA, for 60 minutes at 37 °C. 
￿ Wash in PBS three times for 10 minutes. 
￿ Incubate  with  a  Cy™3-conjugated  AffiniPure  Goat  Anti-Rabbit  IgG  (H+L) 
(Jackson ImmunoResearch), diluited 1:200 in PBS containing 1% BSA for 60 
minutes at 37 °C. 
￿ Wash in PBS three times for 10 minutes. 
￿ Mount with Fluorescence Mounting Medium (Dako) containing 1  g/ml 4',6-
diamidino-2-phenylindole (DAPI) as nuclear counterstain. 
DNA Extraction: 
Genomic  DNA  was  obtained  performing  proteinase  K  digestion  and 
phenol/chloroform (1:1) extraction. 
Cells were treated with lysis buffer (1 ml in a 100mm ø plate containing): 
- Na acetate  0.3 M pH 8 
- Tris-HCl  10 mM pH 7.8 
- EDTA    1 mM pH 8 
- SDS    1% 
Samples were then treated using the following protocol: 
￿ After  adding  5  µl  of  20  mg/ml  of  proteinase  K,  cell  lysate  was  placed  in 
incubation for 1 hour at 37 °C. 
￿ Tubes were then frozen for 30 minutes at -80 °C. 
￿ Samples still frozen were centrifuged at 12,000×g for 10 minutes at 4 °C and 
then supernatant was transferred into a new tube. 
￿ An equal volume of phenol/chloroform was added and mixed. 
￿ Centrifugation at 12,000×g for 2 minutes and supernatant transfer. 
￿ Equal volume of chloroform addition. 
￿ Centrifugation at 12,000×g for 2 minutes and supernatant transfer. 
￿ Addition of 1/10 in volume of Na acetate 3 M pH 5.2. 
￿ Addition of an equal volume (of supernatant) of isopropyl alcohol. MATERIALS AND METHODS 
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￿ Incubation for 10 minutes at room temperature (RT). 
￿ Centrifugation at 12,000×g for 2 minutes and discard of supernatant. 
￿ Pellet was then washed with ethanol 70%. 
￿ After a short centrifuge at 12,000×g ethanol was removed and pellet was let 
briefly dry. 
￿ DNA was dissolved in TE (10 mM Tris HCl pH 7.5, 1 mM EDTA) 
RNA Extraction: 
Total RNA was extracted from cells using TRIzol® reagent. Medium was removed 
from plates and cells washed once or twice with PBS. Cells were lysed using 250 
µl per well. After pipetting, TRIzol® solution was then transferred in a tube and 
the following steps was followed. 
￿ After 15 minutes of incubation on ice, 0.2 ml of chloroform per ml of TRIzol® 
were added. 
￿ Tubes were shaken vigorously for 15 seconds. 
￿ After 2 minutes of incubation at RT samples were centrifuged at 12,000×g for 
15 minutes at 4 °C. 
￿ After separation, the aqueous phase containing RNA was transferred to a 
fresh tube. 
￿ 0.6  ml  of  isopropyl  alcohol  per  ml  of  TRIzol®  were  added  and  mixed 
thoroughly. 
￿ After 30 minutes of incubation on ice, samples were centrifuged at 12,000×g 
for 10 minutes at 4 °C. 
￿ Supernatant was removed and pellet was washed once with ethanol 75%. 
￿ After a short centrifuge at 12000×g ethanol was removed and pellet was let 
briefly dry. 
￿ RNA was dissolved in RNase free water (UltraPure™ DEPC-Treated water). 
cDNA synthesis: 
Concentration of RNA in the samples (and 260/280 ratio) was calculated using 
spectrophotometry,  then  RNA  was  retrotranscribed  using  Invitrogen 
SuperScript™ III Reverse Transcriptase Kit and its standard protocol. 
In the reaction ~1 µg of total RNA was used and 250 ng of random hexamers 
(Promega©) were added as unspecific primers. 
A first mix was prepared adding: 
- Total RNA 
- Primers 
- dNTP mix (10 mM each)  1 µl 
- RNase free water     up to 13 µl MATERIALS AND METHODS 
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The mix was heated to 65 °C for 5 minutes and then tubes were placed on ice for 
at least 1 minute. After a brief spin the following reagents were added: 
- 4 µl       of first-strand buffer 5× 
- 1 µl       of DTT 0.1 M 
- 1 µl (40 units)   of RNaseOUT™ 
- 1 µl (200 units)  of SuperScript™ III Reverse Transcriptase 
Mix  was  kept  to  25  °C  for  5  minutes,  followed  by  60  minutes  at  50  °C; 
temperature  was  then  increased  to  75  °C  for  15  minutes  to  inactivate  the 
enzyme. 
The obtained cDNA was then stored at -20 °C if not directly used. 
PCR: 
Polymerase Chain Reaction was carried out (using primers in Table 2): 
The mix for the reaction was: 
- DNA sample          1-2 µl 
- Buffer 10X Complete       1.25 µl 
- dNTP mix 1 mM        2.5 µl 
- primers (mix of 10 pM/µl each)    0.5 µl 
- AmpliTaq Gold® (Applied Biosystems©)  0.08 µl (0.4 units) 
- DEPC-Treated water        up to 12,5 µl 
PRIMERS FOR RT-PCR 
EXON TO 
TEST 
SKIPPING 
STARTING 
EXON 
FORWARD PRIMER SEQUENCE
(5’ TO 3’) 
REVERSE PRIMER SEQUENCE 
(5’ TO 3’) 
TERMINAL 
EXON 
50  48  CCAAGAAGGACCATTTGACG CCTCCTTCCATGACTCAAGC  53 
53  46  AACCTGGAAAAGAGCAGCAA CCAGGCAAGAAACTTTTCCA  55 
59  56  CCGATGATGCAGTCCTGTTA ACGTGGCTCACGTTCTCTTT  60 
11  9  ACCACCTCTGACCCTACACG CGTTGCCATTTGAGAAGGAT  14 
45  43  GCTCAGGTCGGATTGACATT GAGTGGCTGGTTTTTCCTTG  49 
Table 2 
The amplification was performed using the following temperature cycle: 
￿ 94 °C for 12 minutes 
￿ 30-33 cycles with: 
94 °C for 30 seconds 
60 °C for 30 seconds 
72 °C for 45 seconds 
￿ 72 °C for 10 minutes 
￿ 4° C storage MATERIALS AND METHODS 
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PCR products were then analysed by electrophoresis in agarose gel 0.8-1.6% in 
TAE 1× buffer (40 mM Tris-acetate, 20 mM sodium acetate, 1 mM EDTA, pH 8.0) 
containing SYBR® Safe DNA gel stain. 
  EXPECTED PRODUCTS’ SIZE (bp) 
  PATIENTS  MCQ 
EXON TO 
TEST 
SKIPPING 
EXONS 
RANGE 
FULL-LENGTH  SKIPPED  FULL-LENGTH  SKIPPED 
50  48-53  519 410 752 643 
53  46-55  649 437 1397  1185
59  56-60  558 289 679 410 
11  9-14  616 434 767 585 
45  43-49  749 573 1047  871 
Table 3 
Band extraction from gel and sequencing: 
In order to sequence some of the PCR products, the bands were purified from 
the  agarose  gel  using  the  PureLink™  Quick  Gel  Extraction  Kit  (Invitrogen™) 
according to the manufacturers protocol. 
Sequencing  was  carried  out  by  using  the  DNA  extracted  from  the  bands  as 
template for a further PCR reaction (using the same pair of primers). Amplicons 
were then purified, dried out and sent to BMR sequencing facility. 
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RESULTS 
Transfection set up: 
Myoblasts  cultures  from  different  patients  presented  very  different 
morphologies and development rates. In some cases (patients 8566 and 4445, 
see  below)  cells  showed  quite  slow  proliferation  and  altered  morphology;  in 
these instances we tried to rescue their myogenic phenotype by exposing them 
to  a  different  medium,  specific  for  culturing  satellite  cells  from  single  fibers: 
DMEM, 20% FBS, 10% horse serum and 0.5 % Chicken Embryo Extract (CEE). This 
approach  yielded  some  improvement  in  the  case  of  patient  8566  but  in  the 
other.  
The experimental design with the multiple AO concentrations was modelled after 
that already in use in Dr. S.D. Wilton laboratory (University of Western Australia, 
Australian  Neuromuscular  Research  Institute,  Centre  for  Neuromuscular  and 
Neurological  Disorders,  Perth)  with  which  our  group  is  collaborating  in  this 
project. 
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Transfections: 
 
Figure 14 Cells morphology 24 hours after transfection (original magnification 60×). 
All  cell  cultures  transfected  at  confluence  of  about  90%,  a  condition  that  in 
previous  experiments  in  the  laboratory  had  shown  to  be  well  tolerated  by 
primary  myoblasts  when  using  the  Lipofectamine  2000  reagent  with  plasmid 
DNA. In this case, however, 24 hours after transfection, the cells treated with the 
maximum amount of AO (600 nM) showed signs of sufferance and a lot of them 
were dead and detached from the bottom of the wells; myoblasts treated with 
lower  quantity  of  AO  showed  a  morphology  similar  tothat  of  the  untreated 
controls (Figure 14). 
The  nomenclature  for  naming  AOs  is  the  same  adopted  by  the  team  of  Dr. 
Wilton, which actually synthesized them with their “in house” facility. 
Figure 15 illustrates the nomenclature with an example of AO targeting exon 23 
of mdx mouse. RESULTS 
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Figure 15 AOs nomenclature adopted. 
Test of exon-skipping in wild-type cells: 
AO H50A(+01+30) 
Target on exon 50:  5’ aagAGGAAGT TAGAAGATCT GAGCTCTGAGTGGAAGGCGG 
TAAACCGTTT ACTTCAAGAG CTGAGGGCAA AGCAGCCTGACCTAGCTCCT 
GGACTGACCA CTATTGGAGC CTgtaagtat 3’ 
The PCR primers were positioned in exon 48 (forward) and exon 53 (reverse). 
This antisense oligo produced a skipping that is consistent with the removal of 
the target exon: comparison of amplified products size suggest that the lower 
bands represents an amplified product containing exons from 48 to 53 without 
exon 50 (643 bp), amplified  full-length product (752 bp) is  confirmed by the 
untreated control. In a second transfection with this oligo on MCQ cells, a weak 
signal of a small band appeared at ~400 bp (compatible with exclusion of all 
exons between the exons’ primers) (Figure 16). 
 
Figure 16 
AO H53A(+39+69) 
Target on exon 53:  5’ tttattctag TTGAAAGAAT TCAGAATCAG TGGGATGAAG 
TACAAGAACA CCTTCAGAAC CGGAGGCAAC AGTTGAATGA AATGTTAAAG
GATTCAACAC AATGGCTGGA AGCTAAGGAA GAAGCTGAGC AGGTCTTAGG
ACAGGCCAGA GCCAAGCTTG AGTCATGGAA GGAGGGTCCC TATACAGTAG
ATGCAATCCA AAAGAAAATC ACAGAAACCA AGgttagtat 3’ RESULTS 
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The PCR primers were positioned in exon 46 (forward) and exon 55 (reverse). 
The amplification of cDNA, from cells treated with this oligo, showed a subset of 
shorter amplified products less heavy than the presumed skipping band (1185 
bp). Untreated sample confirm the full-length size (1397 bp) (Figure 17). 
 
Figure 17 
AO H59A(+96+120) 
Target on exon 59:  5’ agAGCTGCCT CCTGAGGAGA GAGCCCAGAA TGTCACTCGG CTTCTACGAA 
AGCAGGCTGA GGAGGTCAAT ACTGAGTGGG AAAAATTGAA CCTGCACTCC 
GCTGACTGGC AGAGAAAAAT AGATGAGACC CTTGAAAGAC TCCgGGAACT 
TCAAGAGGCC ACGGATGAGC TGGACCTCAA GCTGCGCCAA GCTGAGGTGA 
TCAAGGGATC CTGGCAGCCC GTGGGCGATC TCCTCATTGA CTCTCTCCAA 
GATCACCTCG AGAAAGTCAA Ggtaccgtct 3’ 
The PCR primers were positioned in exon 56 (forward) and exon 60 (reverse). 
More than a single skipped product was observed even on the transfection with 
this AO. The confirmed full-length (679 bp) and the skipped product (410 bp) 
seems to be present. In the second transfection more alternative skipping were 
observed (Figure 18). 
 
Figure 18 RESULTS 
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AO H11A(+75+97) 
Target on exon 11:  5’ cagGGGTACA
TGATGGATTT GACAGCCCAT CAGGGCCGGG TTGGTAATAT TCTACAATTG 
GGAAGTAAGC TGATTGGAAC AGGAAAATTA TCAGAAGATG AAGAAACTGA
AGTACAAGAG CAGATGAATC TCCTAAATTC AAGATGGGAA TGCCTCAGGG
TAGCTAGCAT GGAAAAACAA AGCAAgtaag 3’ 
The PCR primers were positioned in exon 9 (forward) and exon 14 (reverse). 
This AO induced skipping compared to the untreated control, however there was 
two  bands  distinguishable  near  the  expected  skipping  product  size.  A  lighter 
band is observable in the transfections with lower quantity of AO (Figure 19). 
 
Figure 19 
AO H45A(-08+19) 
Target on exon 45:  5’ ggtatcttac ag GAACTCCA
GGATGGCATT GGGCAGCGGC AAACTGTTGT CAGAACATTG AATGCAACTG
GGGAAGAAAT AATTCAGCAA TCCTCAAAAA CAGATGCCAG TATTCTACAG 
GAAAAATTGG GAAGCCTGAA TCTGCGGTGG CAGGAGGTCT GCAAACAGCT
GTCAGACAGA AAAAAGAGgt 3’ 
The PCR primers were positioned in exon 43 (forward) and exon 49 (reverse). 
Transfection with this AO induced skipping consistent with removal of exon 45, 
however there was another band distinguishable between the expected skipping 
and the full-length (Figure 20). RESULTS 
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Figure 20 
 
Test of exon-skipping in patients’ primary myoblasts: 
Patient 4969 – treated with AO H50A(+01+30) 
This  patient  carried  a  deletion  of  exon  51  and  his  cells  were  therefore 
transfected with the aim of inducing the skipping of exon 50. 
A single skipping product was detected for the myoblasts of this patient (Figure 
21). 
 
Figure 21 
Patient 4967 – treated with AO H53A(+39+69) 
This  patient  carried  a  deletion  of  exons  48-52  and  his  cells  were  therefore 
transfected with the aim of inducing the skipping of exon 53. RESULTS 
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A single skipping product was detected also for the myoblasts of this patient 
(Figure 22). 
 
Figure 22 
Cells from this patient were also treated over coverslips and investigated for 
dystrophin expression (Figure 23). 
 
Figure 23 Cells stained for dystrophyn A: MCQ control cells; B: treated cells of patient 4967; C: untreated 
cells of patient 4967. (Original magnification 40×) 
Dystrophin  expression  is  noticeable  in  treated  cells,  while  untreated controls 
shown no dystrophin signal. 
 
 
Patient 7547 – treated with AO H59A(+96+120) 
For the purposes of our study cells from this patient were particularly interesting, 
as the boy had been diagnosed as carrier of a point mutation: c.8668+3 A>T in 
intron 58 that was confirmed by sequencing exon 58 (Figure 24) using intronic 
primers targeting outside of the mutation (see Table 4, position of the point 
mutation shown in bold). Our sequencing confirmed that indeed the mutation 
report was correct and, importantly, there were no other base changes either in 
the exon or in the surrounding boundaries. RESULTS 
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INTRONIC PRIMERS TARGETING EXON 58
aaattgacct gggagtttca taaacaagtt ctgagcaccc aggattaatt
ttgagaagaa tgccacaagc caaataagca cttcttttca tctcatttca 
cagGCCTTCA AGAGGGAATT GAAAACTAAA GAACCTGTAA TCATGAGTAC 
TCTTGAGACT GTACGAATAT TTCTGACAGA GCAGCCTTTG GAAGGACTAG 
AGAAACTCTA CCAGGAGCCC AGAGgtaatt gaatgtggaa ctataataac 
atattgatag aaggatcagt ggtgacggag cagcccatcc attcttgctg 
Table 4 
 
Figure 24 Sequence of point mutation in intron 58. 
No RT-PCR analysis had been carried out in this patient, but the fact that he 
showed a classic DMD phenotype suggested that the most likely cause of disease 
was the lack of exon 58 in the mature transcript. For this reason we amplified the 
region 56-60 of its cDNA to verify if this was indeed the case. The amplified 
product  was  indeed  of  the  expected  size  (Figure  25).  The  deletion was  then 
confirmed by sequencing the band. 
 
Figure 25 RESULTS 
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Figure 26 Sequence of the 558 bp amplified product (primers from exon 56 to exon 60) from patient 7547. 
It should be noticed that a lighter band (434 bp) was also consistently obtained 
from the RT-PCR reactions and its length was compatible with the exclusion of 
exon 59. Later sequencing confirmed this hypothesis (Figure 27). 
 
Figure 27 Sequence of the 434 bp amplified product (primers from exon 56 to exon 60) from patient 7547. 
This apparently naturally occurring skipping would restore the correct reading 
frame of the mRNA and hence produce a viable protein. 
Treating the cells with the AO aimed at targeting exon 59 we didn’t see any 
change in the resulting transcribed products. Interestingly, however, we did not 
see any of the extra bands seen with the wild type cells (Figure 29). 
Given the fact that even untreated cells appeared to contain a non-marginal 
amount  of  in  frame  transcript  we  also  investigated  dystrophin  expression  in 
transfected and non-transfected differentiated cultures, but no signal was visible 
in either cases (Figure 28).  RESULTS 
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Figure 28 Cells  stained  for  dystrophyn A:  MCQ control  cells;  B and C:  treated cells  of  patient  7547; D: 
untreated cells of patient 4967. (Original magnification 70× (A) and 40× (B, C and D)). 
Acceptor and donor splice site for intron 58 was analysed for the wild type and 
the mutated sequence: various splicing prediction programs (Table 5) failed to 
find a putative donor site in the mutated sequence or found a low score similar 
to the cryptic sites. 
USED PROGRAM  SCORE IN WT SEQUENCE SCORE IN PATIENT SEQUENCE 
ASSP 
(Wang et al., 2006) 
9.441  5.220 
NNSPLICE 
(Reese et al., 1997) 
0.97  0.43 
NetGene2 
(Brunak et al., 1991) 
0.939  No donor site predicted 
Table 5 
 RESULTS 
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Figure 29 
Patient 8566 – treated with AO H11A(+75+97) 
This  patient  carried  a  deletion  of  exon  12  and  his  cells  were  therefore 
transfected with the aim of inducing the skipping of exon 11. 
Cells from this patient presented a very slow rate of proliferation, even after 
feeding myoblasts with CEE medium they continued to show normal morphology 
but  very slow mitotic  activity. We therefore  had  only  enough  cells for three 
conditions and we decided to transfect them as 300 nM and 100 nM plus the 
negative control (Figure 30). 
Patient 4445 – treated with AO H45A(-08+19) 
Myoblasts from this patient suffered a severe contamination, after a treatment 
with  antibiotic/antimycotic,  survivor  cells  presented  a  “neuronal-like” 
morphology. We tried to transfect the cells anyway, but the low amount of them 
permitted to test only one condition plus a control. 
Unfortunately RT-PCR failed to amplify from the cDNA (Figure 30). 
 
Figure 30 
 RESULTS 
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DISCUSSION 
The designing of AOs to induce exon skipping for the DMD gene generally follows 
a multi-step procedure that can be summarized as: 
- identify candidate target sequences in silico 
- test the efficiency of the AOs both on animal models (cell cultures and in 
vivo) and in human cells 
Ideally, AOs should be tested on patient’s myoblasts but this is often impractical 
due to the difficulties in accessing this kind of material. 
In this work we analyzed the effectiveness of 5 primers, designed to induce the 
skipping  of  as  many  exons,  putting  them  to  the  test  in  cultured  myoblasts 
derived from DMD patients and from a normal control. 
 
The H50A(+01+30) oligo, targeted against the exonic region of the splice site, 
induced the expected exon skipping both in the control and in the myoblasts a 
patient  bearing  the  deletion  of  exon  51.  However,  the  skipping  amount  was 
generally very low and increasing the amount of oligos used for transfection by 
more than an order of magnitude made little difference. Hence, this oligo did not 
appear to be suitable for a possible clinical use. 
 
Control myoblasts transfected with the H53A(+39+69) oligo, directed against a 
predicted ESE inside exon 53, showed a quite unexpected pattern of alternative 
splicing  in  addition  to  the  full-length  product  and  the  desired  skipping;  the 
pattern consisted of several well-defined bands of smaller sizes. The alternative 
bands may have derived from exons, other than the target one, excised from the 
pre-mRNA, or from the use of cryptic splice sites that arose from the interference 
in the normal splice process. Importantly, the presence of the same alternative 
skipping products was confirmed in two different experiments. At present we 
cannot rule out the possibility that some, or even all, of the extra bands were 
actually non-specific PCR products; however, the fact that they were not found 
when  amplifying  the  patient’s  DNA  (see  below)  suggests  that  they  might  be 
derived from the deleted region of the DMD gene. 
Myoblasts  of  a  patient  (deleted  48-58)  were  also  treated  with  this  AO  and 
showed a unique band representing the expected skipping product, in addition 
to the full-length found in the treated and untreated controls. This finding hence 
suggested that the deletion present in the genome of this patient lead to a pre-
mRNA  without  the  regions  involved  in  the  formation  of  the  various  splicing 
pattern shown in the wild type controls. DISCUSSION 
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The oligo efficiency differed greatly between the two cell types, too, as in the 
patient  it  was  possible  to  achieve  a  near  complete  suppression  of  the  non-
skipped mRNA. Again, this finding could point out at the presence of differences 
in  the  splicing  process  in  the  two  nuclear  environments.  Further  sequencing 
analyses  are  planned  to  determine  the  identity  of  the  putative  alternative 
splicing products in the control. 
 
Amongst the five patients’ cultures available, the most interesting was likely the 
one derived from a boy who carries an intronic mutation in the acceptor region 
of  intron  58.  These  cells  were  tranfected  with  the  H59A(+96+120)  oligo  and 
showed  a  thoroughly  unexpected  pattern.  Indeed,  it  RT-PCR  showed  that  all 
samples, including the non transfected control, expressed not only the mRNA 
without  exon  58  but  also  an  alternative  splicing  product  whose  size  was 
compatible with the lack of both exons 58 and 59, plus a band of intermediate 
weight that we could not match to any exon combination. In other words, the in-
frame messenger that we were trying to obtain with the skipping turned out to 
be already present, as sequencing of the band confirmed its identity. Still, the 
patient in question is a true DMD and immunofluorescence analysis failed to 
show any signal of dystrophin in his myoblasts, with or without transfection. A 
quantitative  assay  to  understand  the  proportion  of  the  natural-occurring 
skipping will hopefully clarify the situation. At any rate, transfection with our AO 
did not increase the amount of skipped product, while it reduced the amount of 
the intermediate band. 
When transfecting control cells the AO did induce the formation of the expected 
skipped mRNA, but also of other bands of different sizes. Given that the intensity 
of the bands was clearly proportional to the amount of AO used it was unlikely 
that they were PCR artifacts. 
All in all, these findings seem to indicate that our AO is capable of inducing the 
desired skipping in an intact context (albeit with low efficiency), but it does not 
work in the particular patient we analyzed. 
 
Another  unexpected  finding  was  that  provided  by  the  analysis  of  our    12 
patient.  In  this  case  cells  treated  with  AO  H11A(+75+97)  showed  a  single 
amplified  band  –  even  in  the  untreated  control  –  that  did  not  match  the 
expected size of either the non-skipped or skipped products. Considering the 
length  of  this  band  it  could  represent  a  skipping  of  all  the  exons  comprised 
between  the  primers  used  for  the  PCR.  The  patient’s  observed  splicing  is 
definitely linked to the deletion; in fact, control cells presented the expected PCR 
products size – both for full-length and skipped product –. In terms of skipping DISCUSSION 
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efficiency the AO did not appear to be very active in the normal genomic context, 
as  even  with  the  highest  concentration  the  amount  of  skipped  product  was 
clearly a small fraction of the full-length product. 
Given the problems encountered with this particular batch of cells we are now 
waiting for another vial of cells from Milan’s Telethon biopsy repository in order 
to carry out more transfection experiments with different primers. At any rate, 
our first step will be the sequencing of the  of patient’s amplified cDNA. 
 
Our last primer, AO H45A(-08+19), could only be used on normal cells, as the 
patient’s ones (  46-47) could not be used due to severe contamination of the 
batch that left us with cells incapable of myogenic differentiation. Control cells 
could be skipped, but only with low efficiency and also with the presence of an 
extra  intermediate  band  (between  the  full-length  and  the  expected  skipping 
product). 
 
In  conclusion,  the  work  carried  out  so  far  clearly  indicates  that    finding  a 
promising site for inducing exon skipping in silico does not necessary means that 
it will actually work in vivo. Programs can predict strength of splice sites and ESE 
to  target,  but  their  algorithms  are  clearly  not  fully  reliable  yet  and  seem 
incapable of predicting the interaction between other regions regulating splicing 
processes and the possible outcome of alternative/cryptic splice sites. 
Another important conclusion is that for each AO the skipping efficiency in wild 
type cells does not necessarily forecast the outcome in a mutated environment. 
Keeping this result in mind we suggest that further investigations will need to 
compare patients with the same deletions in terms of missing exons but with 
different breakpoints. In fact, it will be quite possible that two patients with 
deleted, say, for 46-47 will require different AO to achieve the skipping of exon 
45.  
Last but not least, our findings strongly indicated that even apparently “clear cut 
mutations” like exonic deletions can have unexpected effects at the mRNA level 
and therefore antisense therapy for DMD patients will have to be a “case by 
case” approach. 
 
 DISCUSSION 
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